Larimar Therapeutics (LRMR) Liabilities and Shareholders Equity (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $165.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 10.21% year-over-year to $165.3 million; the trailing twelve-month figure through Jun 2026 stood at $648.5 million (down 12.3% YoY), and the FY2025 full-year result was $145.8 million, down 27.16% from the prior year.
• Liabilities and Shareholders Equity climbed to $165.3 million in Q2 2026 per LRMR's latest filing, from $145.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $248.2 million in Q1 2024 and bottomed at $62.9 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $149.8 million across 5 years, with a median of $145.8 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 112.29% in 2024, then tumbled 36.76% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $126.4 million in 2022, then dropped by 24.11% to $95.9 million in 2023, then jumped by 108.71% to $200.2 million in 2024, then decreased by 27.16% to $145.8 million in 2025, then gained by 13.34% to $165.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $165.3 million, $145.8 million, and $187.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.